# RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

> **NCT07625930** · PHASE2 · NOT_YET_RECRUITING · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 184 (estimated)

## Conditions studied

- Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
- **DRUG:** Simvastatin
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT07625930
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2029-04
- **Final completion:** 2031-04
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625930, "RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07625930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*